The current financial score of TScan Therapeutics Inc is 5.67. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 586.00K, representing a year-over-year decrease of 76.66%, while its net profit experienced a year-over-year decrease of 7.35%.
The current valuation score of TScan Therapeutics Inc is 9.04. Its current P/E ratio is -0.17, which is 0.00% below the recent high of -0.17 and -7475.33% above the recent low of -12.74.
The current earnings forecast score of TScan Therapeutics Inc is 6.80. The average price target is 2.67, with a high of 6.00 and a low of 1.00.
The current price momentum score of TScan Therapeutics Inc is 4.98. Currently, the stock price is trading between the resistance level at 0.21 and the support level at 0.13, making it suitable for range-bound swing trading.
The current institutional shareholding score of TScan Therapeutics Inc is 5.00. The latest institutional shareholding proportion is 59.35%, representing a quarter-over-quarter decrease of 20.68%.
The current risk assessment score of TScan Therapeutics Inc is 1.81. The company's beta value is 1.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.